Alan Brooks, PhD

Alan over­sees the company’s in vivo ther­a­peu­tic gene edit­ing programs.

Alan Brooks, PhD's profile photo

Head of Preclinical

Pri­or to join­ing Metageno­mi in Novem­ber of 2019, Alan was Prin­ci­pal Sci­en­tist at Case­bia Ther­a­peu­tics where he ini­ti­at­ed and led CRISPR/​Cas9 genome edit­ing projects for hema­tol­ogy. Pri­or to that, Alan led projects in gene ther­a­py and pro­tein ther­a­peu­tics with a focus on Hemo­phil­ia and rare hema­to­log­i­cal dis­or­ders dur­ing his 10yrs at Bay­er Health­care. Before join­ing Bay­er, Alan worked at sev­er­al biotech star­tups with a focus on car­dio­vas­cu­lar and neu­ro­log­i­cal diseases. 

Alan received his Bach­e­lor of Sci­ence from the Uni­ver­si­ty of Leices­ter in the UK and went on to com­plete a Ph.D. in mol­e­c­u­lar biol­o­gy at the Uni­ver­si­ty of War­wick before join­ing the Glad­stone Insti­tute of Car­dio­vas­cu­lar Dis­ease as a post­doc­tor­al fel­low. In his 30+ years in the pharma/​biotech indus­try, Alan’s research has led to 20 pub­li­ca­tions, numer­ous patent fil­ings and pre­sen­ta­tion of his work at major sci­en­tif­ic meetings.